Losartan Potassium Tablet, Film Coated
Product Images NDC 68071-5041

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 68071-5041). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 5041 9)

Label for Losartan Potassium 25 mg tablets by NuCare Pharmaceuticals, Inc. Contains 90 film-coated tablets for oral administration. Includes the NDC 68071-5041-9 and mentions distribution by Alvordondo Pharma USA, Inc. East Windsor, NJ. The label notes prescription-only use, manufacturer product number R1598090, barcode, and storage instructions to keep at controlled temperatures between 59-86°F.*

FDA Label Image

Figure1 (Losartan Fig1)

A line graph comparing the percentage of patients with the primary endpoint over 66 study months between Atenolol (dotted line) and Losartan Potassium (solid line). The graph includes a noted adjusted risk reduction of 13% with a p-value of 0.021, illustrating treatment effect over time.*

FDA Label Image

Figure2 (Losartan Fig2)

A line graph comparing the percentage of patients with fatal or non-fatal stroke over a 66-month study period between Atenolol and Losartan Potassium. The graph shows a trend with Losartan Potassium having a lower percentage of patients experiencing stroke. Annotated text notes an adjusted risk reduction of 25% with p=0.001.*

FDA Label Image

Figure 3 (Losartan Fig3)

A forest plot chart titled 'Primary Endpoint Events within Demographic Subgroups' comparing Losartan Potassium and Atenolol. It presents hazard ratios with 95% confidence intervals for primary composite and stroke events across various age, gender, race, insulin resistance syndrome (ISN), diabetes, and cardiovascular disease history subgroups. The chart visually indicates which treatment is favored within each subgroup.*

FDA Label Image

Figure-4 (Losartan Fig4)

A line graph comparing the percentage of patients with events over 48 months between Losartan Potassium and placebo groups. The graph indicates a risk reduction of 16.1% with Losartan Potassium, with statistical significance noted (p=0.022). The x-axis represents time in months, and the y-axis shows the percentage of patients experiencing events.*

FDA Label Image

Chemical Structure (Losartan Str)

Chemical structure diagram of Losartan Potassium, showing its molecular arrangement including the potassium ion (K+).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.